Netscientific PLC
LSE:NSCI
Netscientific PLC
LSE:NSCI
Price:
64.5 GBX
1.57%
Market Closed
Updated:
May 14, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-4.7
Current
-4.7
Median
12.9
Industry
Lower
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-4.7
Enterprise Value
/
15.1m
EBITDA
-3.2m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| UK |
|
Netscientific PLC
LSE:NSCI
|
15m GBP | -4.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
182B USD | 19.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
135.1B USD | 55.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.6B USD | 23.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.3B USD | 14.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
107.1B USD | 30.5 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.4B USD | 18.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
58.9B EUR | 18.6 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
371.2B CNY | 28.1 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
51.1B USD | 26.2 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.5B USD | 57.9 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-49.8
2-Years Forward
EV/EBITDA
24.9
3-Years Forward
EV/EBITDA
N/A
You don't have any saved screeners yet
